JiangSu WuZhong Pharmaceutical Development Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. was established in 1994, formerly known as a school run enterprise in the general education system. It was listed on the Shanghai Stock Exchange in 1999 and is known as the "first Chinese general education stock". It is the first listed company in Wuxian (now Wuzhong District) and the sixth listed company in Suzhou. Since its establishment, the company has continuously standardized and improved its governance structure, optimizing its main business through mergers and acquisitions and project investment. Currently, it is involved in industries such as pharmaceuticals, medical aesthetics, and investment. In the pharmaceutical industry, Jiangsu Wuzhong Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary, has gradually built a pharmaceutical industry chain that integrates research and development, production, and sales since its establishment in 2005. Its main products cover fields such as "antiviral/anti infectious, immune regulation, anti-tumor, digestive system, and cardiovascular systems". Pharmaceutical Group is a national contract abiding and trustworthy enterprise, a high-tech enterprise in Jiangsu Province. It is the president of the Suzhou Pharmaceutical Industry Association and the vice president unit of the Jiangsu Pharmaceutical Industry Association. For many consecutive years, it has been ranked among the top 100 comprehensive strength enterprises in the Chinese chemical pharmaceutical industry. In 2020, it was awarded the Suzhou Quality Award and selected for the first batch of 16 potential landmark enterprises in Suzhou's biopharmaceutical cultivation list, as well as the list of leading enterprises in the construction of the Suzhou Advanced Technology Research Institute. At present, the company focuses on high-end generic drugs, first generic drugs, and specialized drugs, steadily promoting innovative drug research and development, vigorously promoting consistency evaluation of injection, tablet, and other varieties, and providing more product support for the company's future core competitiveness improvement. In the medical beauty industry, the company established Jiangsu Wuzhong Aesthetics Biotechnology Co., Ltd. in 2021, with strategic holdings of Chengdu Shangli Huimei Biotechnology Co., Ltd. and Datou Medical Devices (Shenzhen) Co., Ltd. At present, we have the exclusive agency rights in China for the latest injection hyaluronic acid product from Korean medical beauty company Humedix; It has the exclusive sales agency interest in the Chinese Mainland of the AestheFill childlike beauty needle products of Korean medical beauty company RegenBiotech. The company currently focuses on promoting the registration and approval of imported products in China and sales in Hong Kong and Macao, continuing to expand the introduction of cutting-edge high-end products and technical cooperation, and supplementing the high-end injection filling product line in the medical and aesthetic sector; At the same time, actively seeking high-quality assets in other functional skincare products, skin care related medical devices, and other fields, seeking acquisition opportunities for medical beauty related business platforms, creating professional and differentiated medical beauty brands and product clusters, and promoting the company's medical beauty industry's large-scale operation layout. In terms of related investments, Jiangsu Wuzhong Pharmaceutical Industry Investment Co., Ltd. has invested in the establishment and participation of industry funds and merger and acquisition funds mainly focused on the pharmaceutical health industry. Through professional investment and market-oriented operation, it continues to deepen its investment layout and promote the company's extension to the health industry chain. In the 2020 to 2024 five-year strategic development plan, the company has established the pharmaceutical and health industry as the core development direction, and adheres to the dual wheel drive development strategy of industrial development and capital operation. On the one hand, further consolidate and enhance the core position of the pharmaceutical industry; On the other hand, we will focus on cultivating medical beauty and other emerging big health sub industries, forming synergy and complementarity with the existing pharmaceutical industry, forming a big health industry cluster with strong market competitiveness and certain industry status. We are committed to developing into a pharmaceutical big health main board listed company with relatively abundant capital, advanced management concepts, outstanding innovation capabilities, high growth rate, and great potential. |
| Headquarter | Suzhou |
| Establish Date | 6/28/1994 |
| Listed Code | 600200.SH |
| Listed Date | 4/1/1999 |
| Chairman | Qian Qunshan. |
| CEO | Qian Qunshan, Qian Qunying. |
| Website | www.600200.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
